Last reviewed · How we verify
Fe-ASP
Fe-ASP is an iron-asparaginase conjugate that depletes asparagine while delivering iron supplementation.
Fe-ASP is an iron-asparaginase conjugate that depletes asparagine while delivering iron supplementation. Used for Acute lymphoblastic leukemia (ALL).
At a glance
| Generic name | Fe-ASP |
|---|---|
| Also known as | Omalin, Microfer placebo |
| Sponsor | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. |
| Drug class | Asparaginase conjugate |
| Target | Asparagine synthetase (indirect target via asparagine depletion) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Fe-ASP combines asparaginase, an enzyme that catalyzes asparagine depletion (used in acute lymphoblastic leukemia therapy), with iron supplementation. This dual mechanism targets asparagine-dependent leukemic cells while addressing iron deficiency that may occur during intensive chemotherapy. The iron component may reduce anemia-related complications in hematologic malignancies.
Approved indications
- Acute lymphoblastic leukemia (ALL)
Common side effects
- Hypersensitivity reactions
- Coagulopathy
- Hepatotoxicity
- Pancreatitis
- Nausea and vomiting
Key clinical trials
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (PHASE2, PHASE3)
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (PHASE3)
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (PHASE3)
- : Vascular Function in Health and Disease (PHASE1)
- The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction (PHASE1)
- Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia (PHASE4)
- Iron Absorption From Iron Enriched Aspergillus Oryzae in Females Using Stable Isotope Methodology (NA)
- Iron Absorption From Iron-enriched Aspergillus Oryzae (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fe-ASP CI brief — competitive landscape report
- Fe-ASP updates RSS · CI watch RSS
- Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. portfolio CI